Home>Topics>Companies>Mead Johnson & Company

Mead Johnson & Company

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
  1. Mead raises guidance after Q2 results

    Headlines

    Tue, 22 Jul 2014

    Mead Johnson Nutrition Company (NYSE: MJN ) Q2 results : Net Sales: $1,111.1M (+5.3%); R&D Expense: $26.7M (+7.7%); SG&A Expense: $416.9M

  2. Mead Johnson Nutrition misses by $0.01, beats on revenue

    Headlines

    Tue, 22 Jul 2014

    Mead Johnson Nutrition (NYSE: MJN ): Q2 EPS of $0.88 misses by $0.01 . Revenue of $1.11B (+4.7% Y/Y) beats by $10M . Press Release Post your comment!

  3. Mead Johnson ’s 2Q Results Reflect Healthy Volume Growth; Narrow Moat Remains Intact

    Commentary

    Tue, 22 Jul 2014

    Mead Johnson reported solid second-quarter ..... contributing 5%) suggests that Mead Johnson ’s advertising and promotion efforts are strengthening Enfamil ’s brand equity, and ..... the long term, we think Mead Johnson can leverage its brand equity

  4. Mead Johnson Nutrition CO declares $0.375 dividend

    Headlines

    Wed, 11 Jun 2014

    Mead Johnson ( MJN ) declares $0.375/share quarterly dividend , in line with previous. Forward yield 1.73% Payable July 3; for shareholders of record June 23; ex-div June 19. Post your comment!

  5. PJP PowerShares Dynamic Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 5 May 2014

    diagnostics division, point-of-care diagnostics division), Pfizer (Zoetis ZTS), and Bristol-Myers Squibb BMY ( Mead Johnson MJN ). Other deals have been due to cost-cutting potential or firms exiting areas where they lacked critical mass

  6. IHE iShares US Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 5 May 2014

    diagnostics division, point-of-care diagnostics division), Pfizer (Zoetis ZTS), and Bristol-Myers Squibb BMY ( Mead Johnson MJN ). Other deals have been due to cost-cutting potential or firms exiting areas where they lacked critical mass

  7. XPH SPDR S&P Pharmaceuticals ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Mon, 5 May 2014

    diagnostics division, point-of-care diagnostics division), Pfizer (Zoetis ZTS), and Bristol-Myers Squibb BMY ( Mead Johnson MJN ). Other deals have been due to cost-cutting potential or firms exiting areas where they lacked critical mass

  8. New Morningstar Analyst Report for Mead Johnson Nutrition Co

    Stock Reports

    Thu, 1 May 2014

    Despite Mead Johnson 's competitive ..... Around 70% of Mead Johnson 's sales ..... recommending Mead Johnson 's branded ..... value since Mead Johnson began operating ..... entity. Stephen Golsby , who was ..... result. Mead Johnson Nutrition is a supplier ..... with its Enfamil brand as

  9. Mead Johnson Faces a Number of Headwinds, but Moat Remains Intact; Shares Undervalued

    Commentary

    Fri, 31 Jan 2014

    Mead Johnson reported fourth-quarter ..... and we think Mead Johnson should remain on ..... radars. We think Mead Johnson 's business economics ..... strong narrow moat. Mead Johnson generates some ..... advantages gained from Enfamil 's brand equity

  10. China’s Bitter Medicine for Foreign Drug Companies

    Headlines

    Tue, 1 Oct 2013

    in fines on six manufacturers of powdered infant formula, including Illinois producers Abbott Laboratories and Mead Johnson Nutrition , for “various forms of resale price maintenance” that the commission said violated China’s Anti-Monopoly

« Prev12345Next »
Content Partners